Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harrow Inc (NQ: HROW )

9.620 UNCHANGED
Streaming Delayed Price Updated: 12:21 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harrow Inc

< Previous 1 2 3 4 5 Next >
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
From Harrow Health, Inc.
Via Business Wire
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
From Harrow Health, Inc.
Via Business Wire
Harrow Announces Proposed Public Offering of Common Stock
From Harrow Health, Inc.
Via Business Wire
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq
From Harrow Health, Inc.
Via Business Wire
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 5/30
Via Investor Brand Network
Recap: Harrow Health Q1 Earnings
Via Benzinga
Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023
From Harrow
Via Business Wire
NASDAQ:HROW Shareholder Notice: Investigation over Possible Breaches of Fiduciary Duties at Harrow Health, Inc
San Diego, CA -- (SBWIRE) -- 05/16/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Harrow Health, Inc. 
Via SBWire
Why Shares of Harrow Health Are Slumping Friday
The pharmaceutical company announced first-quarter earnings Thursday afternoon. 
Via The Motley Fool
Harrow Announces First Quarter 2023 Financial Results
From Harrow Health, Inc.
Via Business Wire
Earnings Preview For Harrow Health
Via Benzinga
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 5/9
Via Investor Brand Network
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 5/1
Via Investor Brand Network
Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers GSI Technology, Inc. (NASDAQ: GSIT) shares surged 108% to $3.4207. GSI Technology is expected to announce financial results for its fiscal fourth quarter after the market close on May 16,... 
Via Benzinga
Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Harrow
Via Business Wire
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 4/21
Via Investor Brand Network
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 4/4
Via Investor Brand Network
Harrow Health Inc. (NASDAQ: HROW) Climbs to New 52-Week High
Via Investor Brand Network
Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S.
From Harrow
Via Business Wire
Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023
From Harrow
Via Business Wire
Harrow Announces New $100 Million Secured Credit Facility with Oaktree
From Harrow
Via Business Wire
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 3/22
Via Investor Brand Network
Earnings Outlook For Harrow Health
Via Benzinga
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. 
Via Benzinga
Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
From Harrow
Via Business Wire
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
From Harrow
Via Business Wire
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Harrow Health, Inc. (NASDAQ:HROW) Shareholder Notice: Investigation over Possible Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 03/08/2023 -- Harrow Health, Inc. is under investigation over potential securities laws in connection with certain financial statements. 
Via SBWire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.